The HER Family: A Pan Tumor Approach: A Clinical Forum

Proprietary Educational Format:

Activity Overview

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

1.00 CE Credit(s)
Expires: May 11, 2022

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC)
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease

Activity Faculty

tolaney

Sara M. Tolaney, MD, MPH

Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA

Catenacci Daniel pic (1)

Daniel Catenacci, MD

Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL

Liza Villaruz; MD;
consent signed;

Liza C. Villaruz, MD

Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA